These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

594 related items for PubMed ID: 8413475

  • 1. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC.
    N Engl J Med; 1993 Nov 18; 329(21):1524-30. PubMed ID: 8413475
    [Abstract] [Full Text] [Related]

  • 2. Respiratory syncytial virus (RSV) infection in preterm infants and the protective effects of RSV immune globulin (RSVIG). Respiratory Syncytial Virus Immune Globulin Study Group.
    Groothuis JR, Simoes EA, Hemming VG.
    Pediatrics; 1995 Apr 18; 95(4):463-7. PubMed ID: 7700741
    [Abstract] [Full Text] [Related]

  • 3. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
    Pediatrics; 1998 Sep 18; 102(3 Pt 1):531-7. PubMed ID: 9738173
    [Abstract] [Full Text] [Related]

  • 4. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
    American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn.
    Pediatrics; 2003 Dec 18; 112(6 Pt 1):1442-6. PubMed ID: 14654627
    [Abstract] [Full Text] [Related]

  • 5. [Prophylaxis of respiratory syncytial virus (RSV) in preterm infants with/without bronchopulmonary dysplasia: hyperimmune globulin (RSV-IGIV) and palivizumab (MEDI-493)].
    Resch B, Müller W.
    Klin Padiatr; 1999 Dec 18; 211(6):450-5. PubMed ID: 10592925
    [Abstract] [Full Text] [Related]

  • 6. Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis.
    Groothuis JR, Hoopes JM, Hemming VG.
    Adv Ther; 2011 Feb 18; 28(2):110-25. PubMed ID: 21318605
    [Abstract] [Full Text] [Related]

  • 7. A controlled trial of intravenous immune globulin to reduce nosocomial infections in very-low-birth-weight infants. National Institute of Child Health and Human Development Neonatal Research Network.
    Fanaroff AA, Korones SB, Wright LL, Wright EC, Poland RL, Bauer CB, Tyson JE, Philips JB, Edwards W, Lucey JF.
    N Engl J Med; 1994 Apr 21; 330(16):1107-13. PubMed ID: 8133853
    [Abstract] [Full Text] [Related]

  • 8. Infection by the respiratory syncytial virus in infants and young children at high risk.
    Bonnet D, Schmaltz AA, Feltes TF.
    Cardiol Young; 2005 Jun 21; 15(3):256-65. PubMed ID: 15865827
    [Abstract] [Full Text] [Related]

  • 9. Prophylaxis against respiratory syncytial virus in high-risk infants: administration of immune globulin and epidemiological surveillance of infection.
    Handal G, Logvinoff MM, Zegarra N, Allen L, Jesurun A, Levin G, Thida A.
    Tex Med; 2000 May 21; 96(5):58-61. PubMed ID: 10843015
    [Abstract] [Full Text] [Related]

  • 10. Role of antibody and use of respiratory syncytial virus (RSV) immune globulin to prevent severe RSV disease in high-risk children.
    Groothuis JR.
    J Pediatr; 1994 May 21; 124(5 Pt 2):S28-32. PubMed ID: 8169755
    [Abstract] [Full Text] [Related]

  • 11. Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group.
    Rodriguez WJ, Gruber WC, Welliver RC, Groothuis JR, Simoes EA, Meissner HC, Hemming VG, Hall CB, Lepow ML, Rosas AJ, Robertsen C, Kramer AA.
    Pediatrics; 1997 Mar 21; 99(3):454-61. PubMed ID: 9041304
    [Abstract] [Full Text] [Related]

  • 12. Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn.
    Pediatrics; 1997 Apr 21; 99(4):645-50. PubMed ID: 9093323
    [Abstract] [Full Text] [Related]

  • 13. Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants.
    Pediatrics; 1998 Sep 21; 102(3):531-7. PubMed ID: 9724660
    [Abstract] [Full Text] [Related]

  • 14. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. The PREVENT Study Group.
    Pediatrics; 1997 Jan 21; 99(1):93-9. PubMed ID: 8989345
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intravenous immune globulin for the prevention of nosocomial infection in low-birth-weight neonates. The Multicenter Group for the Study of Immune Globulin in Neonates.
    Baker CJ, Melish ME, Hall RT, Casto DT, Vasan U, Givner LB.
    N Engl J Med; 1992 Jul 23; 327(4):213-9. PubMed ID: 1614462
    [Abstract] [Full Text] [Related]

  • 17. Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation - a compassionate use experience.
    DeVincenzo JP, Hirsch RL, Fuentes RJ, Top FH.
    Bone Marrow Transplant; 2000 Jan 23; 25(2):161-5. PubMed ID: 10673674
    [Abstract] [Full Text] [Related]

  • 18. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis.
    Stevens TP, Sinkin RA, Hall CB, Maniscalco WM, McConnochie KM.
    Arch Pediatr Adolesc Med; 2000 Jan 23; 154(1):55-61. PubMed ID: 10632251
    [Abstract] [Full Text] [Related]

  • 19. [Prevention of respiratory syncytial virus infection by SYNAGIS (palivizumab)].
    Pin I, Pilenko C, Bost M.
    Allerg Immunol (Paris); 2002 Dec 23; 34(10):371-4. PubMed ID: 12575622
    [Abstract] [Full Text] [Related]

  • 20. Intravenous palivizumab and ribavirin combination for respiratory syncytial virus disease in high-risk pediatric patients.
    Chávez-Bueno S, Mejías A, Merryman RA, Ahmad N, Jafri HS, Ramilo O.
    Pediatr Infect Dis J; 2007 Dec 23; 26(12):1089-93. PubMed ID: 18043443
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.